Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report)’s share price rose 4.4% on Monday. The stock traded as high as $10.46 and last traded at $10.1250. 1,057,048 shares were traded during mid-day trading, a decline of 79% from the average session volume of 5,111,479 shares. The stock had previously closed at $9.70.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on NTLA shares. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Wall Street Zen cut shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. Barclays assumed coverage on shares of Intellia Therapeutics in a research note on Tuesday, October 6th. They issued an “underweight” rating and a $8.00 target price for the company. Finally, Citizens Jmp set a $30.00 target price on Intellia Therapeutics in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $21.44.
Read Our Latest Analysis on NTLA
Intellia Therapeutics Trading Down 0.8%
The company’s 50-day moving average is $11.80 and its 200-day moving average is $12.92.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 64.74% and a negative net margin of 805.75%. The firm had revenue of $7.16 million for the quarter, compared to the consensus estimate of $9.74 million. During the same quarter last year, the firm posted ($0.92) earnings per share. The business’s revenue for the quarter was down 47.8% on a year-over-year basis. Analysts forecast that Intellia Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.
Insider Buying and Selling at Intellia Therapeutics
In other news, CEO John M. Leonard sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total transaction of $107,910.00. Following the completion of the sale, the chief executive officer owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Intellia Therapeutics
Several institutional investors have recently bought and sold shares of NTLA. Steward Partners Investment Advisory LLC boosted its stake in Intellia Therapeutics by 225.7% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,088 shares of the company’s stock worth $25,000 after purchasing an additional 1,447 shares during the period. Farther Finance Advisors LLC increased its position in shares of Intellia Therapeutics by 289.8% during the third quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock valued at $26,000 after buying an additional 1,594 shares during the period. Parallel Advisors LLC increased its position in shares of Intellia Therapeutics by 267.0% during the third quarter. Parallel Advisors LLC now owns 2,268 shares of the company’s stock valued at $27,000 after buying an additional 1,650 shares during the period. Freestone Grove Partners LP bought a new stake in shares of Intellia Therapeutics during the second quarter valued at about $33,000. Finally, Nykredit A S purchased a new stake in shares of Intellia Therapeutics in the second quarter worth about $33,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.
Featured Articles
- Five stocks we like better than Intellia Therapeutics
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
